Rabbit anti-Human TRAIL Polyclonal Antibody | anti-TRAIL antibody

TRAIL (C13) Antibody

Cat. Num. AAA440037

• Reactivity: Human
• Applications: Western Blot
• Synonyms: TRAIL; Polyclonal Antibody; TRAIL (C13) Antibody; anti-TRAIL antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Specificity: Human TRAIL
• Form/Format: 200 ug/ml rabbit polyclonal IgG in 1 ml PBS containing 0.1 % sodium azide and 0.2% gelatin.
• Concentration: 0.200 mg/ml (varies by lot)

• Applicable Applications for anti-TRAIL antibody: Western Blot (WB)
• Application Notes: TRAIL (C19) DB040 reacts with TRAIL and of mouse, rat, and human origin by western blotting. Western blotting starting dilution 1:200.
• Origin: TRAIL (C13) is provided as an affinity purified rabbit polyclonal antibody, raised against a peptide mapping to the carboxy terminus of human TRAIL.
• Immunogen: Synthetic peptide mapping to the carboxy terminus of human TRAIL.
• Preparation and Storage: Store this product at 4 degree C, do not freeze. The product is stable for one year from the date of shipment.

Western Blot (WB)

Related Product Information for anti-TRAIL antibody

Several members of the growing TNF superfamily can regulate the elimination of immune cells by inducing apoptosis (1). TRAIL (TNF-related apoptosis-inducing ligand) or APO-2L is a member of the TNF superfamily that induces apoptosis by activating the death receptors DR4 and DR5 (2,3). TRAIL is attracting great interesting as an anti-cancer agent because it can induce apoptosis in a broad range of tumor cells, but only rarely in non-transformed cells, and independently of p53 status (2&4). For a time it was a it was unclear how TRAIL could induce apoptosis in tumor cells but not in non-transformed cells, while both of the cell types expressed the DR4 and DR5 death receptors. The discovery that DcR1 or TRID are mostly expressed on normal cells but not in most cancer cell lines helped to solve the puzzle, because these proteins act as decoys for the TRAIL protein (5).

References

1.Pitti R. M., Marsters S.A., Siegfried R., Donahue C.J., Moore A., Ashkenazi A. 1996. Induction of Apoptosis by Apo-2 ligand, a New Member of the Tumor Necrosis Factor Cytokine Family. JBC 271(22):12687-12690.2.Wajant H., Pfizenmaier K., Scheurich P. 2002. TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis 7(5):449-459.3.Phillips T.A., Ni J., Pan G., Ruben S.M., Wei Y., Pace J.L., Hunt J.S. 1999. TRAIL (Apo-2L) and TRAIL Receptors in Human Placentas: Implications for Immune Privilege. Journal of Imm 162:6053-6059.4. 4.Nagane M., Huang H.J., Cavenee W.K. 2001. The potential of TRAIL for cancer chemotherapy. Apoptosis 6(3):191-197.5.Gura T. 1997. How TRAIL Kills Cancer Cells, But not Normal Cells. Science 277(8):768.